Skip to Content

ELISA MAP2K2 Antibody, Biotin

https://biotrend.labm.com/web/image/product.template/68713/image_1920?unique=efde247
Quantity :50µg Clone Number: Aliases:Cardiofaciocutaneous syndrome antibody; CFC syndrome antibody; CFC4 antibody; Dual specificity mitogen activated protein kinase kinase 2 antibody; Dual specificity mitogen-activated protein kinase kinase 2 antibody; ERK activator kinase 2 antibody; FLJ26075 antibody; MAP kinase kinase 2 antibody; map2k2 antibody; MAPK / ERK kinase 2 antibody; MAPK/ERK kinase 2 antibody; MAPKK 2 antibody; MAPKK2 antibody; MEK 2 antibody; MEK2 antibody; MicrotubµLe associated protein kinase kinase 2 antibody; Mitogen activated protein kinase kinase 2 antibody; Mitogen activated protein kinase kinase 2 p45 antibody; MKK 2 antibody; MKK2 antibody; MP2K2_ antibody; OTTHUMP00000165826 antibody; OTTHUMP00000165827 antibody; PRKMK 2 antibody; PRKMK2 antibody Product Type:Polyclonal Antibody Immunogen Species:Homo sapiens () UniProt ID:P36507 Immunogen:Recombinant Dual specificity mitogen-activated protein kinase kinase 2 protein (264-400AA) Raised in:Rabbit Reactivity: Tested Applications:ELISA Background:Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates the ERK1 and ERK2 MAP kinases (By similarity). Clonality:Polyclonal Isotype:IgG Purification Method:>95%, Protein G purified Conjµgate:Biotin Buffer:Preservative: 0.03% Proclin 300 Constituents: 50% Glycerol, 0.01M PBS, PH 7.4 Form:Liquid Stroage:Upon receipt, store at -20°C or -80°C. Avoid repeated freeze. Target Names:MAP2K2 Research Areas:Cancer; Signal transduction

431.60 € 431.6 EUR 431.60 €

431.60 €

Not Available For Sale

This combination does not exist.

Terms and Conditions
30-day money-back guarantee
Shipping: 2-3 Business Days

Our latest content

Check out what's new in our company !

Your Dynamic Snippet will be displayed here... This message is displayed because you did not provide both a filter and a template to use.